AIM ImmunoTech Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.4114
- Today's High:
- $0.4399
- Open Price:
- $0.425
- 52W Low:
- $0.29
- 52W High:
- $1.38
- Prev. Close:
- $0.44
- Volume:
- 93307
Company Statistics
- Market Cap.:
- $24.52 million
- Book Value:
- 0.873
- Revenue TTM:
- $135000
- Operating Margin TTM:
- -14839.26%
- Gross Profit TTM:
- $-715000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -22.9%
- Return on Equity TTM:
- -39.91%
Company Profile
AIM ImmunoTech Inc had its IPO on 1996-07-12 under the ticker symbol AIM.
The company operates in the Healthcare sector and Biotechnology industry. AIM ImmunoTech Inc has a staff strength of 21 employees.
Stock update
Shares of AIM ImmunoTech Inc opened at $0.43 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $0.41 - $0.44, and closed at $0.42.
This is a -4.23% slip from the previous day's closing price.
A total volume of 93,307 shares were traded at the close of the day’s session.
In the last one week, shares of AIM ImmunoTech Inc have slipped by -10.34%.
AIM ImmunoTech Inc's Key Ratios
AIM ImmunoTech Inc has a market cap of $24.52 million, indicating a price to book ratio of 0.4066 and a price to sales ratio of 123.4825.
In the last 12-months AIM ImmunoTech Inc’s revenue was $135000 with a gross profit of $-715000 and an EBITDA of $-19753000. The EBITDA ratio measures AIM ImmunoTech Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, AIM ImmunoTech Inc’s operating margin was -14839.26% while its return on assets stood at -22.9% with a return of equity of -39.91%.
In Q3.3333333333333, AIM ImmunoTech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 36.4%.
AIM ImmunoTech Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.44 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AIM ImmunoTech Inc’s profitability.
AIM ImmunoTech Inc stock is trading at a EV to sales ratio of 10.5849 and a EV to EBITDA ratio of 0.8775. Its price to sales ratio in the trailing 12-months stood at 123.4825.
AIM ImmunoTech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $46.29 million
- Total Liabilities
- $2.90 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $20000
- Dividend Payout Ratio
- 0%
AIM ImmunoTech Inc ended 2023 with $46.29 million in total assets and $0 in total liabilities. Its intangible assets were valued at $46.29 million while shareholder equity stood at $42.70 million.
AIM ImmunoTech Inc ended 2023 with $0 in deferred long-term liabilities, $2.90 million in other current liabilities, 48000.00 in common stock, $-376157000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.76 million and cash and short-term investments were $36.75 million. The company’s total short-term debt was $171,000 while long-term debt stood at $0.
AIM ImmunoTech Inc’s total current assets stands at $41.15 million while long-term investments were $0 and short-term investments were $6.99 million. Its net receivables were $0 compared to accounts payable of $957000.00 and inventory worth $0.
In 2023, AIM ImmunoTech Inc's operating cash flow was $0 while its capital expenditure stood at $20000.
Comparatively, AIM ImmunoTech Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $0.42
- 52-Week High
- $1.38
- 52-Week Low
- $0.29
- Analyst Target Price
- $5.42
AIM ImmunoTech Inc stock is currently trading at $0.42 per share. It touched a 52-week high of $1.38 and a 52-week low of $1.38. Analysts tracking the stock have a 12-month average target price of $5.42.
Its 50-day moving average was $0.54 and 200-day moving average was $0.59 The short ratio stood at 2.7 indicating a short percent outstanding of 0%.
Around 137% of the company’s stock are held by insiders while 1141% are held by institutions.
Frequently Asked Questions About AIM ImmunoTech Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell’Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.